Nextage Therapeutics Debt To Equity vs. Return On Asset
| MCTC Stock | ILA 70.50 1.40 1.95% |
For Nextage Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nextage Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nextage Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nextage Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nextage Therapeutics over time as well as its relative position and ranking within its peers.
Nextage |
Nextage Therapeutics Return On Asset vs. Debt To Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Nextage Therapeutics's current stock value. Our valuation model uses many indicators to compare Nextage Therapeutics value to that of its competitors to determine the firm's financial worth. Nextage Therapeutics is considered to be number one stock in debt to equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nextage Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nextage Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nextage Return On Asset vs. Debt To Equity
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Nextage Therapeutics |
| = | 65.70 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Nextage Therapeutics |
| = | -0.37 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Nextage Return On Asset Comparison
Nextage Therapeutics is currently under evaluation in return on asset category among its peers.
Nextage Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Nextage Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nextage Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Nextage Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Nextage Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.
Nextage Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Nextage Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nextage Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nextage Therapeutics' important profitability drivers and their relationship over time.
Use Nextage Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nextage Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nextage Therapeutics will appreciate offsetting losses from the drop in the long position's value.Nextage Therapeutics Pair Trading
Nextage Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Nextage Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nextage Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nextage Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nextage Therapeutics to buy it.
The correlation of Nextage Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nextage Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nextage Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nextage Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Nextage Therapeutics position
In addition to having Nextage Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 241 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Nextage Stock
To fully project Nextage Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Nextage Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Nextage Therapeutics' income statement, its balance sheet, and the statement of cash flows.